Compare · CI vs FLGT
CI vs FLGT
Side-by-side comparison of The Cigna Group (CI) and Fulgent Genetics Inc. (FLGT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CI and FLGT operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $76.61B, about 147.3x FLGT ($520.0M).
- Over the past year, CI is down 7.0% and FLGT is down 16.2% - CI leads by 9.2 points.
- FLGT has been more active in the news (15 items in the past 4 weeks vs 4 for CI).
- CI has more recent analyst coverage (25 ratings vs 9 for FLGT).
- Company
- The Cigna Group
- Fulgent Genetics Inc.
- Price
- $289.50+0.00%
- $18.28-4.44%
- Market cap
- $76.61B
- $520.0M
- 1M return
- +1.94%
- +20.98%
- 1Y return
- -7.00%
- -16.19%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 4
- 15
- Recent ratings
- 25
- 9
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Fulgent Genetics Inc.
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves insurance, hospitals, and medical institutions. It sells its tests through internal sales force, as well as through independent sales representatives in the United States and internationally. Fulgent Genetics has collaboration with PWNHealth to provide at-home COVID-19 test capabilities. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Latest CI
- EVP, Global CIO Koka Durga Prasad covered exercise/tax liability with 729 shares, decreasing direct ownership by 10% to 6,552 units (SEC Form 4) (withholding tax)
- SEC Form 4 filed by Director Kurian George
- The Cigna Group downgraded by Barclays with a new price target
- The Cigna Group downgraded by Deutsche Bank with a new price target
- Chairman & CEO Cordani David exercised 212,543 shares at a strike of $170.34 and sold $59,114,186 worth of shares (201,878 units at $292.82) as part of a pre-agreed trading plan, increasing direct ownership by 23% to 57,766 units (SEC Form 4)
- The Cigna Group filed SEC Form 8-K: Regulation FD Disclosure
- The Cigna Group Announces Appearance at the BofA Securities 2026 Health Care Conference
- Kayne Anderson Energy Infrastructure Fund Announces Appointment of Michael J. Hennigan as New Independent Director
- SEC Form 144 filed by The Cigna Group
- SEC Form 10-Q filed by The Cigna Group
Latest FLGT
- President and COO Xie Jian sold $38,382 worth of shares (2,146 units at $17.89), decreasing direct ownership by 0.58% to 367,605 units (SEC Form 4) (tax withholding)
- CFO and Treasurer Kim Paul covered exercise/tax liability with 2,087 shares, decreasing direct ownership by 0.57% to 362,545 units (SEC Form 4) to cover taxes
- Chief Scientific Officer Gao Hanlin sold $30,191 worth of shares (1,688 units at $17.89), decreasing direct ownership by 0.17% to 990,374 units (SEC Form 4) (withholding obligation)
- Chief Executive Officer Hsieh Ming covered exercise/tax liability with 4,392 shares, decreasing direct ownership by 0.49% to 893,293 units (SEC Form 4) to satisfy withholding obligation
- Fulgent Presents Updated FID-007 Data at ASCO 2026
- President and COO Xie Jian sold $21,138 worth of shares (1,201 units at $17.60), decreasing direct ownership by 0.32% to 369,751 units (SEC Form 4) (for withholding tax)
- CFO and Treasurer Kim Paul covered exercise/tax liability with 1,168 shares, decreasing direct ownership by 0.32% to 364,632 units (SEC Form 4) (tax liability)
- Chief Scientific Officer Gao Hanlin sold $16,632 worth of shares (945 units at $17.60), decreasing direct ownership by 0.10% to 992,062 units (SEC Form 4) to cover withholding tax
- Amendment: SEC Form SCHEDULE 13D/A filed by Fulgent Genetics Inc.
- Chief Executive Officer Hsieh Ming covered exercise/tax liability with 2,949 shares, decreasing direct ownership by 0.33% to 897,685 units (SEC Form 4) (withholding tax)